Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.
Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer (CRC).
Kopetz says the key question he is asked is what testing should be done on CRC patients. The current guidelindes recommend microsatellite instability testing, which is most commonly done by immunohistochemistry. This testing has important implications for the availability of novel immunotherapies, Kopetz says.